TELA Bio Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $19.3 million, a decrease of 4% from Q2 2025 ($20.2 million).

OviTex Revenue: $13.3 million, up 0.6% year-over-year; OviTex PRS revenue was $5.5 million, down 23% from $7.3 million in Q2 2025.

Gross Profit: $13.9 million (72% gross margin), slightly down from $14.1 million (70% margin) in the prior year.

Operating Expenses: $23.2 million, flat compared to Q2 2025.

Net Loss: $11.3 million, up from $9.9 million in Q2 2025, attributed to higher interest expenses.

Cash Position: $30.4 million at quarter-end.

2Strategic Updates and Business Highlights

Leadership Change: Heather Goetz appointed as new CEO, succeeding founder Antony Koblish.

Product Portfolio: Focus on differentiated offerings in hernia and plastic/reconstructive surgery, with OviTex showing promising clinical outcomes (2.6% recurrence rate).

Sales Strategy: Shift back to a broader sales approach after a pilot program for dedicated PRS reps caused confusion and contributed to revenue decline.

International Growth: International sales rose 26% year-over-year, contributing $3.8 million to revenue.

3Forward Guidance and Outlook

Second Half Recovery: Management expects recovery in the second half of 2026, particularly in the PRS segment, as training and focus on key users are reestablished.

Cost Structure Review: Plans to reduce costs to align with revenue performance; full-year revenue guidance has been withdrawn pending finalization of the cost plan.

4Bad News, Challenges, or Points of Concern

Sales Performance: Decline in OviTex PRS unit volume and challenges with new sales rep productivity, taking longer than the anticipated 6-month ramp-up period.

Competitive Pressures: Ongoing issues with anti-competitive contracting and bundling practices from competitors, impacting OviTex adoption.

Market Dynamics: Shift towards smaller, lower-priced hernia units affecting revenue mix; concentration of sales among a few surgeons poses risks to revenue stability.

5Notable Q&A Insights

Sales Force Update: Current headcount aligns with hiring plans; productivity ramp-up now expected to take 9-12 months instead of 6.

PRS Business: Issues with surgeon availability and pilot program adjustments have impacted performance, but management is optimistic about recovery as key surgeons return.

Competitive Landscape: Management is actively working to improve market access and contracting strategies to combat bundling practices.

Cash Management: The company aims to extend its cash runway through cost reductions while safeguarding critical operations. In conclusion, while TELA Bio faces significant challenges in the short term, particularly in the PRS segment and competitive landscape, the leadership change and strategic adjustments may position the company for recovery and growth in the latter half of 2026.